Five approved Type 1 Gaucher therapies treat the body, not the brain, while a 45-patient gene therapy trial races to close that gap.

Five FDA-approved therapies define Type 1 Gaucher disease treatment: three IV enzyme replacement therapies (imiglucerase, velaglucerase alfa, taliglucerase alfa) and two oral substrate reduction therapies (eliglustat and generic miglustat). All five are chronic, indefinite regimens; none is disease-modifying and none crosses the blood-brain barrier. Eliglustat, the only first-line oral option, carries a CYP2D6 genotype gate that excludes ultrarapid metabolizers, a phenotype found in 8.8 percent of Ashkenazi Jewish individuals, the same population carrying Gaucher disease's highest mutation frequency. No approved Type 1 therapy addresses CNS risk, despite the established GBA1-Parkinson's link in this same patient population.

An estimated 6,000 people live with Type 1 Gaucher disease in the US, a population payers already fund at roughly $300,000 per patient per year for IV enzyme therapy, or a $310,250 list price for eliglustat. That recurring liability is exactly what a durable, one-time therapy could offset. In Phase 1/2 data, four patients treated with Spur Therapeutics' avigbagene parvec (FLT201) discontinued standard therapy and remained off treatment for roughly two years. The program has since entered pivotal Phase 3 as GALILEO-3, with about 45 adults and first patient dosed in July 2026. Payers will demand durability data beyond two years before shifting toward a one-time payment model.

None of the five approved therapies crosses the blood-brain barrier or modifies the disease.

Five questions this report answers:

Q1 - Which Type 1 Gaucher patients are structurally excluded from the only oral therapy today?

Q2 - How close is gene therapy to displacing lifelong enzyme and substrate therapy in Type 1 Gaucher?

Q3 - What reimbursement architecture will payers require before funding a one-time gene therapy over chronic ERT?

Q4 - What deliverables and analyst support come with a Gaucher disease launch-readiness assessment?

Q5 - Why does the GBA1-Parkinson's link matter for a Type 1 Gaucher launch strategy?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#GaucherDisease #RareDisease #GeneTherapy #LaunchReadiness #USMarketAccess

Live report page:  https://axlrx.ai/gaucher-disease/us/launch-readiness/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                                     hello@axlrx.ai

Web-                                     https://axlrx.ai/